

# JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock

**Company** 2024/05/01 22:00:02

**Price**  
 **151.18**  
 USD

**Difference**  4.56%(6.59)



**Contact Details**

JOHNSON & JOHNSON Tel: +1-732-524-0400  
 -- Fax: +  
 One Johnson & Johnson Plaza Web: <http://www.jnj.com>  
 08933 New Brunswick E-mail: -

## Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023            |                        | 2022            |                        | 2021            |                        |
|---------------------------------------|-----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
|                                       | Assets          | Liabilities and equity | Assets          | Liabilities and equity | Assets          | Liabilities and equity |
| <b>Current assets</b>                 | 53,495,000,000  |                        | 55,294,000,000  |                        | 60,979,000,000  |                        |
| <b>Common stock capital</b>           |                 | 3,120,000,000          |                 | 3,120,000,000          |                 | 3,120,000,000          |
| <b>Fixed assets</b>                   | 114,063,000,000 |                        | 132,084,000,000 |                        | 121,039,000,000 |                        |
| <b>Equity capital of a company</b>    |                 | 68,774,000,000         |                 | 76,804,000,000         |                 | 74,023,000,000         |
| <b>Cash and cash equivalents</b>      | 21,859,000,000  |                        | 14,127,000,000  |                        | 14,487,000,000  |                        |
| <b>Accrued liabilities</b>            |                 | 7,149,000,000          |                 | 6,767,000,000          |                 | 8,898,000,000          |
| <b>Other assets</b>                   | -               |                        | -               |                        | -               |                        |
| <b>Current liabilities</b>            |                 | 46,282,000,000         |                 | 55,802,000,000         |                 | 45,226,000,000         |
| <b>Prepayments and accrued income</b> | -               |                        | -               |                        | -               |                        |
| <b>Non-current liabilities</b>        |                 | 52,502,000,000         |                 | 54,772,000,000         |                 | 62,769,000,000         |
| <b>Different income</b>               |                 | -                      |                 | -                      |                 | -                      |
| <b>Other liabilities</b>              |                 | 15,179,000,000         |                 | 13,443,000,000         |                 | 15,399,000,000         |
| <b>Total assets</b>                   | 167,558,000,000 | 167,558,000,000        | 187,378,000,000 | 187,378,000,000        | 182,018,000,000 | 182,018,000,000        |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 131,900 | 152,700 | 141,700 |
| <b>Equity ratio</b>        | 41.04%  | 40.99%  | 40.67%  |
| <b>Debt-equity ratio</b>   | 143.64% | 143.97% | 145.89% |

## Others

|                         | 2023   | 2022   | 2021  |
|-------------------------|--------|--------|-------|
| <b>Tax Expense Rate</b> | 11.53% | 17.42% | 8.33% |

# JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock

## Income statement

|   | 2023           | 2022           | 2021           |
|---|----------------|----------------|----------------|
| Turnover  | 85,152,000,000 | 95,015,000,000 | 93,758,000,000 |
| Net income  | 13,326,000,000 | 17,941,000,000 | 20,878,000,000 |
| EBIT  | 14,054,832,000 | 20,664,750,000 | 21,977,954,000 |
| Operating income before taxes                                 | 15,062,000,000 | 21,725,000,000 | 22,776,000,000 |
| Cash Flow   | 22,791,000,000 | 21,194,000,000 | 23,410,000,000 |
| Net interest income   | 14,000,000     | -400,000,000   | -755,000,000   |
| Research and development expenses                             | 15,048,000,000 | 14,752,000,000 | 14,744,000,000 |
| Income taxes  | 1,736,000,000  | 3,784,000,000  | 1,898,000,000  |
| Result from investments in subsidiaries, associates and other | 0              | 0              | 0              |
| Revenues per employee   | 602,972        | 581,166        | 617,996        |

## Board of Directors

## Members of Management Board

|                    |                               |
|--------------------|-------------------------------|
| Jennifer Doudna    | Member of Board of Directors  |
| Mark McClellan     | Member of Board of Directors  |
| Mary Beckerle      | Member of Board of Directors  |
| Nadja West         | Member of Board of Directors  |
| Paula Johnson      | Member of Board of Directors  |
| Anne Mulcahy       | Member of Board of Directors  |
| D. Davis           | Member of Board of Directors  |
| Darius Adamczyk    | Member of Board of Directors  |
| Eugene Woods       | Member of Board of Directors  |
| Hubert Joly        | Member of Board of Directors  |
| Marilyn Hewson     | Member of Board of Directors  |
| Mark Weinberger    | Member of Board of Directors  |
| Joaquin Duato      | Chairman of Managing Board    |
| James Swanson      | Member of Executive Committee |
| Jennifer Taubert   | Member of Executive Committee |
| Joseph J. Wolk     | Member of Executive Committee |
| Kathy Wengel       | Member of Executive Committee |
| Liz Forminard      | Member of Executive Committee |
| Peter M. Fasolo    | Member of Executive Committee |
| Vanessa Broadhurst | Member of Executive Committee |
| William N. Hait    | Member of Executive Committee |